These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8236152

  • 1. rHuEPO increases urinary excretion of fibrin degradation products in haemodialysed patients.
    Gareau R, Gagnon MG, Ayotte C, Chénard C, Brisson GR.
    Thromb Haemost; 1993 Aug 02; 70(2):373-4. PubMed ID: 8236152
    [No Abstract] [Full Text] [Related]

  • 2. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL, Francis CW, Knutson DW, Marder VJ.
    J Lab Clin Med; 1986 Jun 02; 107(6):534-43. PubMed ID: 3519810
    [Abstract] [Full Text] [Related]

  • 3. [The kidney and fibrinolysis. (2) Urinary excretion of FDP].
    Taura K, Fukushima K, Shinzato K, Harada T, Ogata H.
    Nihon Jinzo Gakkai Shi; 1977 Mar 02; 19(3):139-49. PubMed ID: 560577
    [No Abstract] [Full Text] [Related]

  • 4. [Urinary excretion of fibrin degradation products in children with nephrotic syndrome (author's transl)].
    Bouissou F, Barthe P, Boneu B.
    Arch Fr Pediatr; 1980 Mar 02; 37(3):167-71. PubMed ID: 7469695
    [Abstract] [Full Text] [Related]

  • 5. [Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. First report: Urinary fibrin/fibrinogen degradation products in primary glomerulonephritis (author's transl)].
    Miyamura S.
    Nihon Jinzo Gakkai Shi; 1978 Jan 02; 20(1):67-78. PubMed ID: 650992
    [No Abstract] [Full Text] [Related]

  • 6. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
    Shibata T, Magari Y, Kamberi P, Ishii T, Tomo T, Yasumori R, Nasu M.
    Clin Nephrol; 1995 Aug 02; 44(2):91-5. PubMed ID: 8529315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Fibrin and fibrinogen degradation products in the urine of patients with nephrotic syndrome].
    Ena IaM.
    Sov Med; 1975 Jul 02; (7):85-9. PubMed ID: 1216058
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
    Krawczyk W, Dmoszyńska A, Ledwozyw A, Soroka-Wojtaszko M.
    Acta Haematol Pol; 1993 Jul 02; 24(4):327-31. PubMed ID: 8303978
    [Abstract] [Full Text] [Related]

  • 12. [Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. Second report: Urinary fibrin/fibrinogen degradation products in nephrotic syndrome. (author' transl)].
    Miyamura S.
    Nihon Jinzo Gakkai Shi; 1978 Apr 02; 20(4):315-26. PubMed ID: 671855
    [No Abstract] [Full Text] [Related]

  • 13. [The investigation on early diagnosis of the bladder tumor. I: A study on urinary cytology and urinary fibrin/fibrinogen degradation products (FDP) assay in patient with bladder tumor (author's transl)].
    Tanahashi T.
    Nihon Hinyokika Gakkai Zasshi; 1979 May 02; 70(5):553-62. PubMed ID: 470263
    [No Abstract] [Full Text] [Related]

  • 14. [Correlation between products of fibrin degradation and platelet dysfunction in chronic renal failure. Effects of aspirin].
    Lazzari MA, Pavlovsky M, Martínez Canaveri A.
    Medicina (B Aires); 1977 May 02; 37(2):97-105. PubMed ID: 895494
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical significance of urinary fibrin-fibrinogen degradation products in renal disease].
    Umitsu Y.
    Nihon Jinzo Gakkai Shi; 1976 Jun 02; 18(6):371-87. PubMed ID: 988340
    [No Abstract] [Full Text] [Related]

  • 16. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.
    Sabovic M, Zupan IP, Salobir B, Zupan I, Cernelc P, Lavre J, Vujkovac B.
    Thromb Haemost; 2005 Dec 02; 94(6):1245-50. PubMed ID: 16411401
    [Abstract] [Full Text] [Related]

  • 17. Human recombinant erythropoietin does not induce bone marrow fibrosis in haemodialysed patients.
    Tulliez M, Picard F, Casadevall N, Varet B, Zins B, Naret C, Jacquot C, Peterlongo F, Sundal E.
    Nephrol Dial Transplant; 1989 Dec 02; 4(7):674-5. PubMed ID: 2510069
    [No Abstract] [Full Text] [Related]

  • 18. [Fibrin degradation products in the urine in renal diseases].
    Iversen BM, Ofstad J, Thunold S, Willassen Y.
    Tidsskr Nor Laegeforen; 1976 Jan 20; 96(2):91-3. PubMed ID: 766292
    [No Abstract] [Full Text] [Related]

  • 19. Elastase mediated fibrinolysis in acute promyelocytic leukemia.
    Oudijk EJ, Nieuwenhuis HK, Bos R, Fijnheer R.
    Thromb Haemost; 2000 Jun 20; 83(6):906-8. PubMed ID: 10896247
    [Abstract] [Full Text] [Related]

  • 20. [Urinary crosslinked fibrin degradation products in various renal diseases].
    Kamitsuji H, Whitworth JA, Kincaid-Smith P.
    Nihon Jinzo Gakkai Shi; 1986 Aug 20; 28(8):1137-43. PubMed ID: 3807046
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.